利他唑酮注射剂体内抗菌作用研究

发布时间：2018-05-25 18:26

  本文选题：利他唑酮 + 利奈唑胺　； 参考：《中国抗生素杂志》2016年11期

【摘要】：目的研究利他唑酮(LT-01)注射剂对小鼠细菌感染的保护作用,以此来评价LT-01的体内抗菌效果。方法用LT-01注射剂及利奈唑胺注射液对2株革兰阳性菌感染小鼠败血症模型进行保护作用研究,记录小鼠的存活数,并用DAS2.1.1软件计算半数有效量(ED_(50))等参数,并比较两药的差异。结果 LT-01注射剂对万古霉素耐药肠球菌(VRE)感染小鼠败血症模型的ED_(50)=1.036mg/kg,对耐甲氧西林金黄色葡萄球菌(MRSA)感染小鼠败血症模型ED_(50)=1.271mg/kg,与市售利奈唑胺注射液相比均无显著差异(P0.05)。结论实验结果表明LT-01对革兰阳性球菌有很好的抗菌作用,提示LT-01是一种可用于临床治疗耐药革兰阳性球菌感染的药物,值得进一步开发研究。
[Abstract]:Objective to study the protective effect of Ritazolone LT-01) injection on bacterial infection in mice and evaluate the antibacterial effect of LT-01 in vivo. Methods the protective effects of LT-01 injection and linazolamide injection on the septicemia model of two Gram-positive bacteria infected mice were studied. The survival number of mice was recorded and the parameters such as half effective dose (LD50) were calculated by DAS2.1.1 software and the difference between the two drugs was compared. Results the septicemia model of mice infected with vancomycin resistant enterococci and methicillin-resistant staphylococcus aureus infected with LT-01 injection was 1.036 mg / kg and 1.271 mg / kg respectively. Conclusion the experimental results show that LT-01 has a good antibacterial effect on Gram-positive cocci, suggesting that LT-01 is a drug that can be used in clinical treatment of drug-resistant Gram-positive cocci infection, and it is worthy of further development and study.
【作者单位】： 解放军第三0二医院药学部药物临床试验中心;北京大学第一医院临床药理研究所;四川赛卓药业股份有限公司;
【基金】：国家十二五重大新药创制 国家重大科技专项课题(No.2014ZX09201001-008)
【分类号】：R965
，

本文编号：1934216